The Name Behind the Semaglutide Weight-Loss Tablet

Why there are multiple semaglutide names and what each one actually treats

Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and signals fullness to the brain. The same active ingredient appears under three brand names in the UK, and the name tells you everything about what it's licensed to do.

Wegovy (injection) has been available for weight management since its NICE recommendation in 2023. Wegovy tablets arrived in June 2026 and carry the same weight-management licence, adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related health condition such as high blood pressure or obstructive sleep apnoea. The full picture on Wegovy tablets covers eligibility in more depth.

Rybelsus is where confusion tends to creep in. It is also oral semaglutide, but the tablet strengths (3mg, 7mg and 14mg) are licensed for type 2 diabetes, not weight management. A page searching for 7mg semaglutide tablets will generally surface Rybelsus content, which has no bearing on the weight-loss product. The Wegovy tablet schedule uses entirely different strengths: 1.5mg, 4mg, 9mg and 25mg. If you see a strength outside that sequence being described as a weight-loss dose, it's worth querying it with a prescriber.

Ozempic, for completeness, is injectable semaglutide licensed for type 2 diabetes. The MHRA has been clear that it is not approved for weight loss, and prescribing it off-label for that purpose is a decision with real regulatory and safety implications. Worth knowing before you ask your GP for it by name.

The practical decision: tablet or injection?

Once you've confirmed the name (Wegovy) the next question most people have is whether the tablet or the injection suits their life better. That's ultimately a clinical conversation, but the practical differences are real.

The tablet is taken first thing in the morning, before anything else: a small sip of plain water (up to about 120ml), then at least 30 minutes before food, coffee or other oral medicines. It's a routine that works well for people who are already used to starting the day in a particular order, the tablet before the kettle goes on, essentially. There's no injection technique to learn, no sharps disposal, and no need for fridge space. Room-temperature storage makes it considerably simpler for anyone who travels regularly. You can read more about how often the tablet is taken and what the schedule involves.

The injection, by contrast, is once weekly and bypasses any absorption complexity. The comparison of semaglutide tablet options goes into this in more detail, but the core point is this: both routes are prescription-only, both require clinical assessment, and the right format depends on your health history, your preferences and what your prescriber concludes after reviewing your consultation.

Trial evidence for the tablet comes from the OASIS 4 study, a phase-3 trial of 307 adults over 64 weeks. Average weight loss was around 13.6% versus approximately 2.4% on placebo. Among participants who stayed fully adherent to treatment, the figure reached around 17%. The MHRA's approval announcements and the manufacturer's UK communications provide further context on the clinical programme.

What having the right name doesn't tell you about getting started

Knowing the tablet is called Wegovy is a useful starting point, but it doesn't tell you whether you meet the licensed criteria, whether the tablet or injection is more appropriate for you, or whether anything in your health history needs careful consideration first. Semaglutide is a prescription-only medicine, and that's not a technicality, it reflects the fact that the same features that make it effective (slowing digestion, altering appetite signalling) also mean it interacts meaningfully with other conditions and medications.

The most common side effects with the tablet are gastrointestinal: nausea, loose stools, vomiting and indigestion, reported by the majority of participants in the trial, though most described them as mild to moderate and temporary, particularly after dose changes. A prescriber will want to know about your full medication list, any history of pancreatitis or gallbladder problems, and your current weight and BMI, all of which shape whether Wegovy tablets are the right fit. The NHS semaglutide page covers the full side-effect and contraindication picture in plain language.

For a broader look at weight-loss treatment options available through a regulated UK pharmacy, including how they differ and what the consultation process covers, our treatment overview is a good place to start. The brand name details for oral semaglutide go into further background if you want the regulatory history before deciding anything. One factual note on cost: as of summer 2026, the Wegovy tablet is available on a private prescription only, NICE has not yet appraised it, so there is no NHS route for weight management. Where to get the Wegovy tablet in the UK walks through what a legitimate private prescription service looks like and what to check before you proceed.